<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697655</url>
  </required_header>
  <id_info>
    <org_study_id>PMC008</org_study_id>
    <nct_id>NCT03697655</nct_id>
  </id_info>
  <brief_title>Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma</brief_title>
  <acronym>PREDATOR</acronym>
  <official_title>Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polish Myeloma Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioscience, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Myeloma Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical
      relapse or progression of multiple myeloma (MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is composed of two phase 2 randomized multi-center substudies:

        -  PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical
           relapse

        -  PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD)
           reappearance
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>treatment arm and control (observation) arm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (ESF)</measure>
    <time_frame>from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks</time_frame>
    <description>To compare (EFS) between daratumumab arm and observation arm after randomization of patients with biochemical relapse of Multiple Myeloma and MRD reappearance in Multiple Myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>from randomization till progression or death from any cause, up to 129 weeks</time_frame>
    <description>ORR as determined by Investigator evaluation, defined as the percentage of subjects achieving an objective response (i.e. partial response or better), using IMWG Consensus Panel 1 response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>throughout the duration of the study, no longer than 6 years</time_frame>
    <description>To compare overall survival between arms</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PREDATOR-BR Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-BR Cohort B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>n=46, Control Group, Observation (no treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-MRD Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDATOR-MRD Cohort B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>n=59, Control Group, Observation (no treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab 20 MG/ML [Darzalex]</intervention_name>
    <description>Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks</description>
    <arm_group_label>PREDATOR-BR Cohort A</arm_group_label>
    <arm_group_label>PREDATOR-MRD Cohort A</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PREDATOR-BR:

        Inclusion Criteria:

          1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of
             therapy; single or tandem autologous stem cell transplant is not considered a separate
             line of therapy and is not mandatory; and have achieved at least PR to last line of
             therapy, and who experience asymptomatic biochemical progression not meeting criteria
             for SPR.

          2. Males and females ≥18 years of age.

          3. Life expectancy of more than 3 months.

          4. ECOG performance status of 0-2.

          5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase
             (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.

          6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.

          7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as
             follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma
             creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.

          8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including
             pre-menopausal women who have had a tubal ligation) and for all women not meeting the
             definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone
             surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all
             other women, documentation must be present in medical history confirming that the
             patient is not of childbearing potential.

          9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice
             complete abstinence from heterosexual intercourse during the study.

         10. Male subjects must agree to use a latex condom during sexual contact with females of
             childbearing potential while participating in the study and for at least 28 days
             following discontinuation from the study even if he has undergone a successful
             vasectomy.

         11. Voluntary written informed consent.

        Exclusion Criteria:

          1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG
             criteria.

          2. Patient with SPR - significant paraprotein relapse defined as doubling of the
             M-component in two consecutive measurements separated by &lt; 2 months; or an increase in
             the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or
             involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive
             measurements separated by &lt; 2 months.

          3. Patients who have already started or received post-transplant maintenance or
             consolidation treatment.

          4. Subject has received daratumumab or other anti-CD38 therapies previously.

          5. Patients not able to tolerate daratumumab or required concomitant medication and
             procedures.

          6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in
             1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is required for
             subjects suspected of having COPD and subjects must be excluded if FEV1 &lt;50% of
             predicted normal.

          7. Known moderate or severe persistent asthma, or a history of asthma within the last 2
             years, or currently has uncontrolled asthma of any classification. (Note that subjects
             who currently have controlled intermittent asthma or controlled mild persistent asthma
             are allowed to participate in the study).

          8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          9. Plasma cell leukemia.

         10. Waldenström's macroglobulinemia.

         11. CNS involvement.

         12. Pregnant or lactating females.

         13. Radiotherapy within 14 days before randomization. Seven days may be considered if to
             single area.

         14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a
             major surgery.

         15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

         16. Rate-corrected QT interval of electrocardiograph (QTc) &gt; 470 msec on a 12-lead ECG
             during screening.

         17. Patient who in investigator's opinion is unable to comply with the protocol
             requirements.

         18. Uncontrolled hypertension or diabetes.

         19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two
             weeks prior to enter the study.

         20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B
             virus vaccine are eligible.

         21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid
             cancer, carcinoma in situ of the cervix, or prostate cancer &lt; Gleason Grade 6 with
             stable prostate specific antigen levels or cancer considered cured by surgical
             resection alone.

         22. Any clinically significant medical disease or condition that, in the Investigator's
             opinion, may interfere with protocol adherence or a subject's ability to give informed
             consent.

        PREDATOR-MRD:

        Inclusion Criteria:

          1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of
             therapy; single or tandem autologous stem cell transplant is not considered a separate
             line of therapy and is not mandatory; and have achieved CR with negative MRD to the
             last line of therapy and who remain in CR MRD negative. The last response assessment
             confirming CR MRD negative status based on assessment of bone marrow sample using flow
             cytometry with sensitivity of at least 10-5 needs to be performed not earlier than 3
             months before inclusion to the study.

          2. Males and females ≥18 years of age.

          3. Life expectancy of more than 3 months.

          4. ECOG performance status of 0-2.

          5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase
             (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.

          6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.

          7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as
             follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma
             creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.

          8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including
             pre-menopausal women who have had a tubal ligation) and for all women not meeting the
             definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone
             surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all
             other women, documentation must be present in medical history confirming that the
             patient is not of childbearing potential

          9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice
             complete abstinence from heterosexual intercourse during the study.

         10. Male subjects must agree to use a latex condom during sexual contact with females of
             childbearing potential while participating in the study and for at least 28 days
             following discontinuation from the study even if he has undergone a successful
             vasectomy.

         11. Voluntary written informed consent.

        Exclusion criteria:

          1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG
             criteria.

          2. Patient with SPR - significant paraprotein relapse defined as doubling of the
             M-component in two consecutive measurements separated by &lt; 2 months; or an increase in
             the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or
             involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive
             measurements separated by &lt; 2 months.

          3. Patients who have already started or received post-transplant maintenance or
             consolidation treatment.

          4. Subject has received daratumumab or other anti-CD38 therapies previously.

          5. Patients not able to tolerate daratumumab or required concomitant medication and
             procedures.

          6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in
             1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is required for
             subjects suspected of having COPD and subjects must be excluded if FEV1 &lt;50% of
             predicted normal.

          7. Known moderate or severe persistent asthma, or a history of asthma within the last 2
             years, or currently has uncontrolled asthma of any classification. (Note that subjects
             who currently have controlled intermittent asthma or controlled mild persistent asthma
             are allowed to participate in the study).

          8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          9. Plasma cell leukemia.

         10. Waldenström's macroglobulinemia.

         11. CNS involvement.

         12. Pregnant or lactating females.

         13. Radiotherapy within 14 days before randomization. Seven days may be considered if to
             single area.

         14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a
             major surgery.

         15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

         16. Rate-corrected QT interval of electrocardiograph (QTc) &gt; 470 msec on a 12- lead ECG
             during screening.

         17. Patient who in investigator's opinion is unable to comply with the protocol
             requirements.

         18. Uncontrolled hypertension or diabetes.

         19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two
             weeks prior to enter the study.

         20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B
             virus vaccine are eligible.

         21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3
             years except a) adequately treated basal cell, squamous cell skin cancer, thyroid
             cancer, carcinoma in situ of the cervix, or prostate cancer &lt; Gleason Grade 6 with
             stable prostate specific antigen levels or cancer considered cured by surgical
             resection alone.

         22. Any clinically significant medical disease or condition that, in the Investigator's
             opinion, may interfere with protocol adherence or a subject's ability to give informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polish Myeloma Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
    <phone>+48 504 065 262</phone>
    <email>k.m.jamroziak@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominik Dytfeld, MD, PhD</last_name>
    <phone>+48 602 464 708</phone>
    <email>dytfeld@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Jamroziak, MD, PhD</last_name>
      <phone>+48 22 349 64 78</phone>
      <email>k.m.jamroziak@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Dytfeld, MD, PhD</last_name>
      <phone>+48 602464708</phone>
      <email>dytfeld@me.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

